Skip to main content

Elopag 20 mg ( Eltrombopag)

Elopag is identified on this website as a product containing eltrombopag in a stated 20 mg strength. Eltrombopag is an oral prescription medicine that stimulates the thrombopoietin receptor, which plays a role in platelet production. The actual product packaging and official leaflet should be checked to confirm its composition, strength and formulation.

The active ingredient identified for Elopag on this website is eltrombopag. It is a thrombopoietin receptor agonist used in selected patients with certain conditions involving low platelet counts or impaired blood-cell production.

Eltrombopag may be prescribed for selected patients with chronic immune thrombocytopenia, severe aplastic anemia and, in certain treatment settings, thrombocytopenia associated with chronic hepatitis C. The approved indications depend on the applicable product authorization and prescribing information. A healthcare professional must determine whether treatment is appropriate.

Eltrombopag is a prescription medicine. It requires medical assessment and monitoring. Patients should not start taking it without a prescription and professional guidance.

Eltrombopag belongs to a class of medicines known as thrombopoietin receptor agonists. These medicines stimulate a receptor involved in the production of platelets in the bone marrow.

Eltrombopag stimulates the thrombopoietin receptor on certain precursor cells in the bone marrow. This supports the development of megakaryocytes, which are responsible for producing platelets. The resulting increase in platelet production may help selected patients with conditions associated with low platelet counts.

Immune thrombocytopenia, or ITP, is a condition in which the immune system contributes to the destruction of platelets and may also affect platelet production. People with ITP may experience easy bruising, small red or purple spots on the skin, nosebleeds, bleeding gums or other bleeding symptoms. Eltrombopag may be prescribed for selected patients with persistent or chronic ITP.

Eltrombopag may be used in specific severe aplastic anemia treatment settings. The exact role depends on the patient's condition, treatment history and applicable prescribing information. Aplastic anemia is a serious bone marrow disorder. Treatment should be managed by an appropriate specialist.

Eltrombopag can increase platelet production in selected patients, but an increase in platelet count does not necessarily mean that the underlying condition has been cured. The treatment goal depends on the diagnosis. In ITP, for example, the aim is generally to maintain a platelet count that reduces clinically important bleeding risk.

The time needed to see a response can vary according to the patient's condition, dose and individual response. Platelet counts are monitored during treatment to evaluate effectiveness. Patients should not increase their dose if they do not see an immediate improvement. Treatment decisions should be based on professional assessment and laboratory results.

Eltrombopag is taken by mouth. The patient should follow the prescribed dose and the administration instructions in the official leaflet for the specific product. The correct dose depends on the medical condition, age, liver function, platelet count and other factors. The stated 20 mg strength does not establish the correct number of tablets for an individual patient.

Eltrombopag is commonly prescribed once daily in several treatment settings. However, the exact schedule depends on the indication and the prescribing healthcare professional's instructions. Do not change the frequency without professional guidance.

Food can affect eltrombopag absorption. The U.S. reference prescribing information for PROMACTA recommends taking it without a meal or with a meal containing no more than 50 mg of calcium. The instructions for the specific product should always be checked before use.

Milk contains calcium, which may reduce eltrombopag absorption when taken too close to the medicine. Follow the food and timing instructions in the applicable product leaflet. A pharmacist can help plan the timing of eltrombopag and calcium-containing foods.

Some vitamins and mineral supplements contain calcium, iron, magnesium, aluminium or zinc. These substances can interfere with eltrombopag absorption. The U.S. reference prescribing information recommends separating PROMACTA from products containing polyvalent cations by at least 2 hours before or 4 hours after. Check the relevant product instructions and ask a pharmacist about your supplements.

Follow the missed-dose instructions in the official product leaflet or ask a pharmacist or healthcare professional. Do not take an extra dose to compensate for a missed dose unless specifically instructed by your healthcare professional.

Do not stop treatment independently. Platelet counts may decrease after eltrombopag is discontinued. The healthcare professional should decide whether treatment needs to continue, change or stop.

Reported adverse reactions vary according to the condition being treated and the patient's circumstances. They may include nausea, diarrhoea, headache, fatigue, cough, upper respiratory tract symptoms and muscle pain. Not every patient experiences these effects. Patients should report persistent, severe or unusual symptoms to their healthcare professional.

Yes. Eltrombopag can cause liver-function abnormalities and potentially serious liver injury. Healthcare professionals may request liver function tests before and during treatment. Yellowing of the skin or eyes, dark urine, unusual fatigue or upper-right abdominal pain should be assessed promptly.

Yes. Excessively high platelet counts may increase the risk of thrombotic or thromboembolic complications. Blood clots have also been reported in certain treatment settings. Patients should seek urgent medical attention for symptoms such as sudden chest pain, difficulty breathing, sudden weakness or one-sided leg swelling.

Yes. Platelet counts are monitored to assess treatment response and guide dose decisions. Liver function tests may also be required. The frequency of testing depends on the medical condition, treatment stage and applicable prescribing information.

Whether eltrombopag is appropriate depends on the patient's medical history, condition and potential risks. People with liver disease, a history of blood clots, other blood disorders or previous allergic reactions should discuss these issues with their healthcare professional. The official prescribing information should be reviewed for contraindications and warnings. Patients should not decide independently whether the medicine is suitable.

Patients who are pregnant, planning pregnancy or who may become pregnant should discuss eltrombopag with their healthcare professional. The potential benefits and risks must be assessed individually using the applicable prescribing information.

Patients should ask their healthcare professional about alcohol use during treatment, particularly if they have liver disease or other medical conditions. Alcohol-related risks should be considered alongside the medicine's liver-related precautions.

The specific manufacturer of Elopag has not been independently verified for this website content. Check the original packaging, official product leaflet and relevant regulatory records for the manufacturer's name and address.

Products may contain the same active ingredient but differ in manufacturer, formulation, packaging and regulatory authorization. Do not assume that every product is interchangeable without professional confirmation.

Review the original packaging, product leaflet, manufacturer information, batch number and expiry date. Where possible, confirm the product's regulatory status with the relevant medicines authority. A pharmacist or authorized supplier may help assess the product documentation.

Eltrombopag is a prescription medicine. Patients should obtain it through legitimate pharmaceutical channels and follow the prescription and supply requirements applicable in their country.

No. Regulatory approvals and prescribing instructions can differ between countries. Always consult the official product information applicable to the product and location.

Useful sources include official prescribing information, national medicines regulatory authorities, recognized medical references and the patient leaflet supplied with the specific product. A pharmacist or prescribing healthcare professional can help interpret this information.